GlassScriptPhysician profile
Roger Sullivan
NPI 1346534484
$10,171.00
in general payments reported to CMS, 2019-2025
36 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,350 · 2020: $515 · 2021: $420 · 2022: $1,550 · 2023: $1,732 · 2024: $2,357 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,103 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,102.97 |
| Education | $232.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,300.79 | 2019-2025 | Rinvoq, Skyrizi |
| Arcutis Biotherapeutics, INC. | $901.30 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $886.06 | 2019-2025 | Adbry, Anzupgo |
| Genzyme Corporation | $770.55 | 2022-2025 | |
| Pfizer INC. | $661.48 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $549.83 | 2019-2025 | Ilumya |
| Dermavant Sciences, INC. | $545.16 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $467.39 | 2019-2025 | |
| Lilly USA, LLC | $450.77 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $405.69 | 2022-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $305.17 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $294.28 | 2019-2025 | Nemluvio |
| Amgen INC. | $290.65 | 2020-2025 | Otezla, Enbrel, Otezla |
| Regeneron Healthcare Solutions, INC. | $268.24 | 2019-2024 | Libtayo |
| Incyte Corporation | $253.86 | 2022-2024 | Opzelura |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $241.48 | 2019-2025 | Cimzia, Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $238.28 | 2019-2025 | Cabtreo |
| Biofrontera INC. | $183.15 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Mayne Pharma Commercial LLC | $150.69 | 2019-2025 | |
| Almirall LLC | $141.48 | 2019-2025 | Klisyri |
| Organon LLC | $140.46 | 2024-2025 | Vtama |
| Epi Health, LLC | $111.41 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $85.55 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $82.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $79.99 | 2021 | |
| Celgene Corporation | $62.21 | 2019 | |
| Sensus Healthcare, INC. | $57.68 | 2021 | |
| Sandoz INC. | $56.93 | 2023-2024 | Hyrimoz |
| Organogenesis INC. | $42.78 | 2022 | |
| Dermira, INC. | $39.06 | 2019 | |
| Botanix Sb INC | $31.21 | 2025 | Sofdra |
| Aclaris Therapeutics, INC. | $20.13 | 2019 | |
| Genentech USA, INC. | $16.12 | 2020 | |
| Journey Medical Corporation | $14.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.84 | 2023 | Seglentis |
| Next Science LLC | $11.45 | 2023 | Surgx, Blastx, Xperience |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roger Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.